Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Linkage to Care for Patients With HDV
  • CME
  • CE

Loading...
Your patient tests positive for hepatitis delta virus (HDV). Now what? Listen as 2 experts discuss challenges and opportunities in linking patients with HDV to care.
Kosh Agarwal, MD
Graham R. Foster, FRCP, PhD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: June 30, 2022 Expiration: June 29, 2023

You can think of the “D” in HDV as standing for difficult, disadvantaged, and dangerous. Hepatitis delta virus (HDV) is difficult to diagnose, is often diagnosed in disadvantaged patient populations, and leads to dangerous sequelae.

Listen as Dr. Kosh Agarwal and Dr. Graham R. Foster and discuss challenges and opportunities for linking patients to care after a positive test for HDV.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement screening practices that ensure that patients at risk for HDV infection are promptly diagnosed and appropriately counseled

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Kosh Agarwal, MD

Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
King's College Hospital NHS Foundation Trust
London, United Kingdom

Kosh Agarwal, MD: consultant: Arbutus, Assembly, Aligos, Biotest, Bluejay, Drugfram, GlaxoSmithKline, Gilead, Janssen, Immunocore, Merck, Roche, Sobi, Vir; research funds: Abbott, Gilead, MSD.
Graham R. Foster, FRCP, PhD

Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Graham R. Foster, FRCP, PhD: consultant/advisor/speaker: AbbVie, Gilead, GlaxoSmithKline, MSD, Biogen and UniQure.

Staff

Julie Skowronski, NP
Julie Skowronski, FNP, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, nurse practitioners, and other healthcare professionals who provide care for patients with HDV infection.

Goal

The goal of this program is to improve healthcare professionals’ awareness of HDV and the importance of screening in patients with HBV, as well as their competence in treating patients with HBV/HDV coinfection.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 30, 2022, through June 29, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Related Content

Dr Stefan Zeuzem discusses his take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Stefan Zeuzem, MD Released: December 5, 2022

Dr Nancy Reau discusses her take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 2, 2022

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Expert summaries of key data in older patients with HBV, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Nancy Reau, MD Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings